Search - tctmd.com

Displaying 481 - 500 of 978

Sort: Relevancy | Date

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

News Conference News ESC 2018

Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy

Michael O'Riordan

August 27, 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

August 27, 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

August 27, 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

MITRA-FR: No Benefit of MitraClip in Functional MR

News Conference News ESC 2018

MITRA-FR: No Benefit of MitraClip in Functional MR

August 27, 2018

Ten-Year Follow-up Proves Disappointing for Bilateral Arterial Grafts in ART

News Conference News ESC 2018

Ten-Year Follow-up Proves Disappointing for Bilateral Arterial Grafts in ART

August 26, 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

News Conference News ESC 2018

FUTURE Results Confirm More Deaths With FFR-Guided Treatment Choice

August 26, 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

August 25, 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

News Conference News ESC 2018

MATRIX: 1-Year Results Confirm Superiority of Transradial PCI

Michael O'Riordan

August 25, 2018

CULPRIT-SHOCK: 1-Year Results Continue to Support Culprit-Only PCI for Shock Patients

News Conference News ESC 2018

CULPRIT-SHOCK: 1-Year Results Continue to Support Culprit-Only PCI for Shock Patients

August 25, 2018

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

News Daily News

AHA Scientific Statement Aims to Raise Awareness of Chagas Disease and Risk for Cardiomyopathy

August 24, 2018

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

News Daily News

‘Immediate’ Return to Normal Flow Post-PCI in ORBITA-Like Patients

Michael O'Riordan

August 23, 2018

Diversity in Heart Failure Trials Still Falls Short

News Daily News

Diversity in Heart Failure Trials Still Falls Short

August 22, 2018

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

Podcast TCTMD Talking Points

ABSORB III: 3-Year Outcomes From a Randomized Trial of a Bioresorbable Scaffold vs a Metallic DES in Patients With Coronary Artery Disease

August 22, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.